Impact of Multimorbidity on Colon Cancer Survival
Author Information
Author(s): Wang Su-Hung, Koseki Mitsuhiro, Sheu Ming‑Jen, Li Huang-Lan, Lin Ying-Jia, Yang Ching-Chieh, Ho Chung-Han
Primary Institution: Chi Mei Medical Center
Hypothesis
This study aimed to understand the comorbidity risks for long-term colon cancer survivors using a real-world population database.
Conclusion
The study indicated that managing comorbidities may improve survival outcomes for colon cancer patients, especially those with severe comorbidities.
Supporting Evidence
- 82.23% of colon cancer survivors had no comorbidities.
- Patients with mild comorbidities had a 4.56 times higher risk of mortality.
- Patients with severe comorbidities had a 12.67 times higher risk of mortality.
- Mortality rates were significantly higher in patients with higher CCI scores.
- Older individuals had higher overall mortality among the three CCI groups.
- Patients with a BMI <18.5 had significantly higher overall mortality.
- Smoking and drinking habits were more prevalent in patients with severe comorbidities.
- Integrated care models are suggested for managing comorbidities in cancer patients.
Takeaway
Having more than one health problem can make it harder for colon cancer survivors to live longer, so doctors need to help them manage these other health issues.
Methodology
The study used data from the Taiwan Cancer Registry and assessed comorbidities using the Charlson Comorbidity Index, applying Cox regression models to estimate mortality risks.
Potential Biases
The study may have survivorship bias due to a high proportion of patients with no comorbidities, affecting generalizability.
Limitations
The study's retrospective design may not capture all relevant patient data, and there is a potential for misclassification bias regarding comorbidities.
Participant Demographics
The mean age of participants was 68.84 years, with a higher proportion of males in severe comorbidity groups.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 3.93-5.28 for mild comorbidities; 95% CI: 11.15-14.40 for severe comorbidities
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website